Barclays raised the firm’s price target on Boston Scientific (BSX) to $133 from $125 and keeps an Overweight rating on the shares. The company reported a Q2 beat on strong growth in Watchman and Farapulse, the analyst tells investors in a research note. The firm increased estimates post the report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific Reports Strong Q2 2025 Results
- Boston Scientific Reports Strong Q2 Growth Amid Challenges
- Boston Scientific’s Strong Financial Performance and Positive Outlook Earns Buy Rating
- Boston Scientific’s Strong Performance and Growth Potential Reinforce Buy Rating
- Boston Scientific price target raised to $127 from $124 at BTIG